|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 150.2 USD | +0.56% |
|
+0.23% | -21.51% |
ALNYLAM PHARMACEUTICALS INC - REITERATED 2023 GUIDANCE FOR COMBINED NET PRODUCT REVENUES OF $1,200 MLN TO $1,285 MLN
| 1st Jan change | Capi. | |
|---|---|---|
| -21.51% | 19B | |
| +41.79% | 54.04B | |
| -0.56% | 41.92B | |
| +49.62% | 41.96B | |
| -7.20% | 28.35B | |
| +12.59% | 26.35B | |
| +6.92% | 13B | |
| +24.91% | 12.19B | |
| +29.60% | 12.28B | |
| -5.64% | 11.49B |
ALNYLAM PHARMACEUTICALS, INC. 
